1 Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal
dissection and endoscopic mucosal resection for early gastric cancer. Dig
Endosc 2016; 28: 3–15.
2 Tate DJ, Klein A, Sidhu M, et al. Endoscopic submucosal dissection for
suspected early gastric cancer: absolute versus expanded criteria in a large
Western cohort (with video). Gastrointest Endosc 2019; 90: 467–479.e4.
3 Otsuka T, Sugimoto M, Ban H, et al. Severity of gastric mucosal atrophy
affects the healing speed of post-endoscopic submucosal dissection ulcers.
World J Gastrointest Endosc 2018; 10: 83–92.
4 Yoshizawa Y, Sugimoto M, Sato Y, et al. Factors associated with healing of
artificial ulcer after endoscopic submucosal dissection with reference to
Helicobacter pylori infection, CYP2C19 genotype, and tumor location: multicenter randomized trial. Dig Endosc 2016; 28: 162–172.
5 Wang J, Wu Q, Yan Y, et al. Effectiveness of fibrin sealant as hemostatic
technique in accelerating ESD-induced ulcer healing: a retrospective study.
Surg Endosc 2020; 34: 1191–1199.
6 Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump
inhibitors for the management of gastric endoscopic submucosal dissectioninduced artificial ulcer: a systematic review with meta-analysis. Medicine
(Baltimore) 2019; 98: e15860.
7 Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for
peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized
controlled trials. Mayo Clin Proc 2007; 82: 286–296.
8 Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice
guidelines for peptic ulcer disease 2015. J Gastroenterol 2016; 51: 177–194.
9 Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice
guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;
51: 751–767.
10 Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a
novel potassium-competitive acid blocker, vs. lansoprazole for the healing of
erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240–251.
11 Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan
20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy
adult male subjects--a randomised open-label cross-over study. Aliment
Pharmacol Ther 2015; 42: 719–730.
12 Andersson K, Carlsson E. Potassium-competitive acid blockade: a new
therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294–
307.
13 Ohkuma K, Iida H, Inoh Y, et al. Comparison of the early effects of
vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way
crossover study. J Clin Biochem Nutr 2018; 63: 80–83.
14 Maruoka D, Arai M, Kasamatsu S, et al. Vonoprazan is superior to proton
pump inhibitors in healing artificial ulcers of the stomach post-endoscopic
submucosal dissection: a propensity score-matching analysis. Dig Endosc
2017; 29: 57–64.
15 Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of
artificial gastric ulcers after endoscopic submucosal dissection: prospective
H. Ban et al.
randomized controlled trial. Dig Endosc 2017; 29: 576–583.
16 Ban H, Sugimoto M, Otsuka T, et al. Letter: a potassium-competitive
acid blocker vs a proton pump inhibitor for healing endoscopic submucosal
dissection-induced artificial ulcers after treatment of gastric neoplasms.
Aliment Pharmacol Ther 2017; 46: 564–565.
17 Hirai A, Takeuchi T, Takahashi Y, et al. Comparison of the effects of
vonoprazan and lansoprazole for treating endoscopic submucosal dissectioninduced artificial ulcers. Dig Dis Sci 2018; 63: 974–981.
18 Ishida T, Dohi O, Yamada S, et al. Clinical outcomes of vonoprazan-treated
patients after endoscopic submucosal dissection for gastric neoplasms: a prospective multicenter observation study. Digestion 2020. DOI: 10.1159/
000507807
19 Japanese Gastric Cancer Association. Japanese gastric cancer treatment
guidelines 2018 (5th edition). Gastric Cancer 2020. DOI: 10.1007/s10120020-01042-y
20 Tatemichi M, Sasazuki S, Inoue M, Tsugane S; Japan Public Health Center
Study Group. Different etiological role of Helicobacter pylori (Hp) infection
in carcinogenesis between differentiated and undifferentiated gastric cancers:
a nested case-control study using IgG titer against Hp surface antigen. Acta
Oncol 2008; 47: 360–365.
21 Takahashi K, Sato Y, Kohisa J, et al. Vonoprazan 20 mg vs lansoprazole 30
mg for endoscopic submucosal dissection-induced gastric ulcers. World J
Gastrointest Endosc 2016; 8: 716–722.
22 Hung KW, Knotts RM, Faye AS, et al. Factors associated with adherence to
Helicobacter pylori testing during hospitalization for bleeding peptic ulcer
disease. Clin Gastroenterol Hepatol 2020; 18: 1091–1098 e1.
23 Arkkila PE, Seppälä K, Kosunen TU, et al. Eradication of Helicobacter
pylori improves the healing rate and reduces the relapse rate of nonbleeding
ulcers in patients with bleeding peptic ulcer. Am J Gastroenterol 2003; 98:
2149–2156.
24 Kakushima N, Fujishiro M, Yahagi N, Kodashima S, Nakamura M, Omata
M. Helicobacter pylori status and the extent of gastric atrophy do not affect
ulcer healing after endoscopic submucosal dissection. J Gastroenterol
Hepatol 2006; 21: 1586–1589.
25 Lim JH, Kim SG, Choi J, Im JP, Kim JS, Jung HC. Risk factors of delayed
ulcer healing after gastric endoscopic submucosal dissection. Surg Endosc
2015; 29: 3666–3673.
26 Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of Helicobacter
pylori: what should be the gold standard? World J Gastroenterol 2014; 20:
12847–12859.
This is an open access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivatives
License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Clin. Biochem. Nutr. | May 2021 | vol. 68 | no. 3 | 263
©2021 JCBN
...
論文の公開元へ
